Development of Blueberry-Derived Extracellular Nanovesicles for Immunomodulatory Therapy
Pharmaceutics · 10.08.2023 · 15 (8) · 2115
DOI: 10.3390/pharmaceutics15082115 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 10.08.2023. Verfasst von Tuong Ngoc-Gia Nguyen und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Faculty of Health, Deakin University, Geelong Waurn Ponds Campus, Geelong, VIC 3216, Australia. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deakin University Postgraduate Research Scholarship, Australian Research Council.
Abstract (Originalsprache)
Over the past decade, there has been a significant expansion in the development of plant-derived extracellular nanovesicles (EVs) as an effective drug delivery system for precision therapy. However, the lack of effective methods for the isolation and characterization of plant EVs hampers progress in the field. To solve a challenge related to systemic separation and characterization in the plant-derived EV field, herein, we report the development of a simple 3D inner filter-based method that allows the extraction of apoplastic fluid (AF) from blueberry, facilitating EV isolation as well as effective downstream applications. Class I chitinase (PR-3) was found in blueberry-derived EVs (BENVs). As Class I chitinase is expressed in a wide range of plants, it could serve as a universal marker for plant-derived EVs. Significantly, the BENVs exhibit not only higher drug loading capacity than that reported for other EVs but also possess the ability to modulate the release of the proinflammatory cytokine IL-8 and total glutathione in response to oxidative stress. Therefore, the BENV is a promising edible multifunctional nano-bio-platform for future immunomodulatory therapies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine, Faculty of Health, Deakin University, Geelong Waurn Ponds Campus, Geelong, VIC 3216, Australia.
- Laboratory of Tumor Molecular and Cellular Biology, College of Life Sciences, Shaanxi Normal University, 620 West Chang'an Avenue, Xi'an 710119, China.
- College of Materials and Chemical Engineering, Minjiang University, Fuzhou 350108, China.
- School of Medicine, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, VIC 3800, Australia.
ORCID-Profile: Tuong Ngoc-Gia Nguyen, Cuong Viet Pham, Rocky Chowdhury
Förderung
- Deakin University Postgraduate Research Scholarship
- Australian Research Council
Zitieren
APA
Nguyen, T. N., Pham, C. V., Chowdhury, R., Patel, S., Jaysawal, S. K., Hou, Y., Xu, H., Jia, L., Duan, A., Tran, P. H., & Duan, W. (2023). Development of Blueberry-Derived Extracellular Nanovesicles for Immunomodulatory Therapy. Pharmaceutics, 15(8), 2115. https://doi.org/10.3390/pharmaceutics15082115
Vancouver
Nguyen TN, Pham CV, Chowdhury R, Patel S, Jaysawal SK, Hou Y, et al. Development of Blueberry-Derived Extracellular Nanovesicles for Immunomodulatory Therapy. Pharmaceutics. 2023;15(8):2115. doi:10.3390/pharmaceutics15082115
BibTeX
@article{Nguyen2023,
author = {Nguyen, Tuong Ngoc-Gia and Pham, Cuong Viet and Chowdhury, Rocky and Patel, Shweta and Jaysawal, Satendra Kumar and Hou, Yingchun and Xu, Huo and Jia, Lee and Duan, Andrew and Tran, Phuong Ha-Lien and Duan, Wei},
title = {Development of Blueberry-Derived Extracellular Nanovesicles for Immunomodulatory Therapy},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {8},
pages = {2115},
doi = {10.3390/pharmaceutics15082115}
}
EUVIMED